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Abstract
Background: WHO-guidelines for prevention of mother-to-child transmission of HIV-1 in resource-limited settings
recommend complex maternal antiretroviral prophylaxis comprising antenatal zidovudine (AZT), nevirapine single-dose
(NVP-SD) at labor onset and AZT/lamivudine (3TC) during labor and one week postpartum. Data on resistance development
selected by this regimen is not available. We therefore analyzed the emergence of minor drug-resistant HIV-1 variants in
Tanzanian women following complex prophylaxis.
Method: 1395 pregnant women were tested for HIV-1 at Kyela District Hospital, Tanzania. 87/202 HIV-positive women
started complex prophylaxis. Blood samples were collected before start of prophylaxis, at birth and 1–2, 4–6 and 12–16
weeks postpartum. Allele-specific real-time PCR assays specific for HIV-1 subtypes A, C and D were developed and applied
on samples of mothers and their vertically infected infants to quantify key resistance mutations of AZT (K70R/T215Y/T215F),
NVP (K103N/Y181C) and 3TC (M184V) at detection limits of ,1%.
Results: 50/87 HIV-infected women having started complex prophylaxis were eligible for the study. All women took AZT
with a median duration of 53 days (IQR 39–64); all women ingested NVP-SD, 86% took 3TC. HIV-1 resistance mutations were
detected in 20/50 (40%) women, of which 70% displayed minority species. Variants with AZT-resistance mutations were
found in 11/50 (22%), NVP-resistant variants in 9/50 (18%) and 3TC-resistant variants in 4/50 women (8%). Three women
harbored resistant HIV-1 against more than one drug. 49/50 infants, including the seven vertically HIV-infected were
breastfed, 3/7 infants exhibited drug-resistant virus.
Conclusion: Complex prophylaxis resulted in lower levels of NVP-selected resistance as compared to NVP-SD, but AZT-
resistant HIV-1 emerged in a substantial proportion of women. Starting AZT in pregnancy week 14 instead of 28 as
recommended by the current WHO-guidelines may further increase the frequency of AZT-resistance mutations. Given its
impact on HIV-transmission rate and drug-resistance development, HAART for all HIV-positive pregnant women should be
considered.
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Introduction
Mother-to-child transmission of HIV-1 in resource-limited
settings accounts for almost 16% of all new HIV-1 infections in
Sub-Saharan Africa [1]. Antiretroviral drugs for HIV-1-infected
pregnant women and their infants are an essential component in
reducing mother-to-child transmission of HIV-1. The non-
nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine
(NVP) has been widely applied as single dose (NVP-SD)
prophylaxis at the onset of labor [2]. However, due to the low
genetic barrier of NVP even a single dose frequently induces viral
resistance [3–10], thus compromising the success of subsequent
NNRTI-containing highly active antiretroviral treatment
(HAART) if initiated within 6–12 month after prophylaxis [11–
13]. To reduce viral resistance as well as to further lower the
vertical transmission risk of HIV-1, the WHO guidelines for the
prevention of mother-to-child transmission (PMTCT) of 2006 and
2010 [14,15] recommend complex antiretroviral prophylaxis. This
is composed of antenatal zivoduvine (AZT) for three (2006) or six
months (2010), NVP-SD at labor onset and AZT/lamivudine
(3TC) during labor and for one week postnatally. In 2008,
complex prophylaxis was recommended by the national Tanza-
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Monotherapy of antiretroviral drugs, however, inherently involves
the risk of drug resistance development. Selection of AZT-resistant
virus during prenatal AZT monotherapy might decrease the
efficacy of future AZT-containing prophylactic and therapeutic
regimens. Furthermore, as both NVP and 3TC rapidly select for
drug-resistant virus, dual- or multi-resistant HIV-1 variants could
emerge. Even minor drug-resistant HIV-1 variants representing
small proportions of the total viral population can impair
virological outcome of HAART [17–24]. Hence, it is mandatory
to characterize the resistance development including minority
species following complex prophylaxis, which to our knowledge
has not been assessed for the WHO-recommended complex
prophylaxis regimen. The aim of this study was to evaluate the
emergence of HIV-1 variants resistant against AZT, NVP and/or
3TC following complex antiretroviral prophylaxis in a rural
district hospital in Kyela, Mbeya Region, Tanzania. For this
purpose, we developed, evaluated and applied highly sensitive
allele-specific PCR (ASPCR) assays enabling the detection and
quantification of three key mutations for AZT resistance (K70R,
T215Y and T215F), the two most common NVP-associated
resistance mutations (K103N and Y181C) and the most frequent
3TC-selected mutation M184V in the pol open reading frame with
a detection limit of ,1% [25,26]. ASPCR assays were adapted for
HIV-1 subtypes A, C and D which are common in Sub-Saharan
Africa and prevalent in Mbeya Region, Tanzania [27]. Subse-
quently, blood specimens from HIV-1-infected pregnant Tanza-
nian women and their vertically infected infants who had taken
complex antiretroviral prophylaxis were analyzed.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the local Mbeya Medical
Research and Ethics Committee, the National Institute for
Medical Research of Tanzania and the ethical committee of
Charite ´ – Universita ¨tsmedizin Berlin in Germany. We obtained
informed written consent from all participants involved in our
study.
Clinical samples and study design
The present study analyzes the HIV-1 resistance development
in HIV-1-infected Tanzanian women and their infants as part of
an observational study at Kyela District Hospital, Mbeya Region
between October 2008 and September 2009 [28]. In March 2008,
complex antiretroviral prophylaxis was introduced as the standard
PMTCT regimen at Kyela District Hospital. According to WHO
PMTCT guidelines from 2006 [14] and National Tanzanian
PMTCT guidelines [16], women were offered complex antiretro-
viral prophylaxis composed of AZT starting in gestational week 28
(26300 mg per day), or as soon as possible thereafter, followed by
NVP-SD (200 mg) at labor onset and AZT (300 mg) every three
hours plus 3TC (150 mg) every 12 hours during labor, followed by
a one week postpartum course of AZT (26300 mg per day) and
3TC (26150 mg per day). Infants received NVP-SD (2 mg/kg)
within 72 hrs after birth and AZT (4 mg/kg per day) for one week.
In case the mother had taken antenatal AZT for less than four
weeks, the infant received postnatal AZT for four weeks. Blood
samples were collected before start of AZT prophylaxis, during
pregnancy, at delivery and at 1–2, 4–6, and 12–16 weeks
postnatally.
202 of 1395 (14.5%) pregnant women tested for HIV-1 during
antenatal care were HIV-1 positive. 122 HIV-positive women
were included in the observational study as they fulfilled the
following eligibility criteria: no HAART, no clinical or immuno-
logical indication to start HAART, i.e. CD4 cell count .=200
cells/mm3 and clinical categories A or B according to CDC
classification, age .=18 years, absence of other severe diseases
including psychiatric disorders, written informed consent [28].
Eventually, 87 of the 122 eligible women started AZT prophylaxis
during pregnancy [28]. Women and if applicable their HIV-
infected infants were included in the resistance analysis if they had
taken AZT in pregnancy for at least two weeks, if they had taken
NVP at labor onset, and if a delivery sample and at least two
postnatal (1–2 weeks, 4–6 weeks and/or 12–16 weeks) plasma
samples were available. In the case of home delivery, the last
antenatal specimen was used as ‘‘delivery sample’’. Additionally, a
baseline sample prior to AZT intake had to be amplifiable in order
to establish an individual cut-off for resistance detection [29]. No
woman received any other antiretroviral drugs during the study
period. Children of the study cohort were breastfed.
Detection and quantification of drug-resistant HIV-1
Drug-resistant mutations in the pol open reading frame of HIV-
1 were detected by ASPCR which is an established and widely
used method for the analysis of minor drug-resistant HIV-1
variants [5,29–33]. The assay is composed of two consecutive real-
time PCRs. The outer real-time PCR amplified a reverse
transcriptase (RT) fragment comprising the codons of interest
(codons 22 to 236 of the RT) and was also used for quantification
of viral load. The inner ASPCR was composed of one real-time
PCR reaction with discriminatory ability for mutant sequences
using selective primers and one generic real-time PCR reaction
amplifying both wild-type and mutant sequences using non-
selective primers (Table 1). For each resistance mutation, an
individual inner ASPCR assay had to be designed. In total, seven
ASPCR assays were performed per sample: two AZT mutations
confering high level resistance (T215Y, T215F) and one early
AZT mutation (K70R) confering only low level resistance but
indicating for emergence of AZT-resistance; additionally the two
most common NVP-selected resistance mutations (K103N and
Y181C) and the most frequent 3TC-selected mutation M184V
were analysed [34,35] (details in Materials and Methods S1).
Vertical transmission of HIV-1
The HIV-status of newborns was determined by RT-PCR of
blood specimens collected 4–6 weeks after birth using the above
described outer PCR. Infants with a positive PCR result at 4–6
week were defined to be HIV-infected whereas infants with a
negative PCR result were assumed to be not HIV-infected. If the
4–6 week sample was lacking, an earlier blood sample from
delivery or week 1–2 was analysed. If the earlier sample was PCR-
positive, the child was considered to be HIV-infected 4–6 weeks
after birth as well; if the earlier blood sample was PCR-negative,
the infant was excluded from calculation of transmission rate as
the HIV status week 4–6 after birth could not be determined.
Population-based sequencing and determination of HIV-
1 subtype
For population-based sequencing of the 644 bp product
generated by outer PCR, the automated sequencer 3130xl Genetic
Analyzer (Applied Biosystems, Darmstadt, Germany) and the HIV
SEQ MIX B, D and G of the Viroseq HIV-1 Genotyping System
version 2.0 (Abbott, Wiesbaden, Germany) were applied. To
exclude sample mix-up and to confirm vertical HIV-1 transmis-
sion, phylogenetic analysis of maternal and infant sequences
generated by population-based sequencing was performed using
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of the pol sequence was performed using the REGA HIV-1
subtyping tool [37].
Statistical analysis
The non-parametric Mann-Whitney U test was used to assess
significant differences between two independent samples whereas
the Wilcoxon signed-rank test was used to analyze repeated
measurements. Chi-Square test or Fisher’s exact test were applied
to analyze the independence of categorical variables. Testing of
significant correlations between two continuous variables was done
by Pearson’s correlation coefficient. For descriptive analysis,
median and interquartile ranges (IQR) were calculated. Two-
sided tests were used and p,0.05 was considered statistically
significant. Drug-resistant HIV-1 variants carrying the K103N
(AAC) mutation and the K103N (AAT) mutation were summed to
obtain the total proportion of virus carrying the K103N mutation.
Statistical analysis was carried out using PASW Statistics 18 (SPSS
Inc., Chicago, Illinois, USA).
Results
Sample characteristics
Of 87 women having started complex prophylaxis, 50 women
fulfilled the eligibility criteria and were included in the resistance
analysis, together with their seven vertically HIV-infected infants.
Median baseline characteristics before start of prophylaxis were:
age 28 years (IQR 26–30), HIV-1 viral load 1.25610
4 copies/mL
(IQR 4.4610
3–4.5610
4) and CD4 cell counts of 390 cells/mm
3
(IQR 260–492). The median maternal viral load was 2.9610
3
copies/mL (IQR 1.4610
3–6.8610
3) at delivery, 1.7610
3 copies/
mL (IQR 1.3610
3–5.8610
3) 1–2 weeks postpartum, 1.2610
4
copies/mL (IQR 6.3610
3–3.7610
4) 4–6 weeks postpartum and
2.5610
4 copies/mL (IQR 1.2610
4–3.7610
4) 12–16 weeks
postpartum. Compared to baseline viral load, maternal viral loads
at delivery and 1–2 weeks postpartum were significantly lower
(both p,0.001) but reached similar levels at 4–6 weeks (p=0.45)
and at 12–16 weeks (p=0.54) postpartum, respectively. Women
received AZT during pregnancy for a median of 53 days (IQR 39–
64). Thirty-seven (74%) women delivered at Kyela District
Hospital whereas 13 (26%) women delivered at home or in
another health facility. Regardless of the place of delivery, all
women took NVP-SD before birth. Thirty-four of 37 women who
delivered at Kyela District Hospital received intrapartum AZT/
3TC. Forty-one women took AZT/3TC postpartum for one week,
while another five women took AZT but not 3TC postpartum. In
total, 86% (43/50) of women took at least one dose of 3TC. Forty-
four (88%) infants received NVP-SD after birth, including all 37
newborns born at Kyela District Hospital and 7/13 infants born at
another place. Forty-five (90%) newborns took AZT postnatally;
42 of whom for one week and three for four weeks. Forty-nine of
50 infants including all HIV-infected infants were breastfed. 28%
Table 1. Oligonucleotide sequences of primers used in outer and allele-specific PCR (ASPCR).
Assay and primer name Nucleotide sequence Nucleotide position (HXB2) Fragment size (bp)
Outer-PCR
HIV-TZ FOR 59- AAACAATGGCCATTRACAGARGA-39+ 2613–2635
HIV-TZ REV 59- GGATGGAGTTCATAICCCATCCA-392 3234–3256 644
K70R ASPCR
TZ-K70 FOR 1 59- GCIATAAARAARAARGACAGYACTC-39+ 2733–2757
TZ-K70R FOR 2 59- GCIATAAARAARAARGACAGYACTCG-39+ 2733–2758
TZ-K70 REV 59- CCCACATCYAGTACTGTYACTGATTT-392 2859–2884 152
K103N ASPCR
TZ-K103 FOR 59- GGCCTGAAAATCCATAYAAYACTCC-39+ 2701–2725
TZ-K103 REV1 59- CCCACATCYAGTACTGTYACTGATTT-392 2859–2884
TZ-K103N(C) REV3 59- CCCACATCYAGTACTGTYACTGATTGG-392 2858–2884
TZ-K103N(T) REV4 59- CCCACATCYAGTACTGTYACTGATTGA-392 2858–2884 184
Y181C ASPCR
TZ-Y181/M184 FOR 59- AAATCAGTRACAGTACTRGATGTRGG-39+ 2859–2884
TZ-Y181 REV1 59- ATCCTACATACAARTCATCCATRTATTGA-392 3092–3120
TZ-Y181C REV3 59- ATCCTACATACAARTCATCCATRTATTGCC-392 3091–3120 262
M184V ASPCR
TZ-Y181/M184 FOR 59- AAATCAGTRACAGTACTRGATGTRGG-39+ 2859–2884
TZ-M184 REV1 59- TCAGATCCTACATAYAARTCATCCA-392 3101–3124
TZ-M184V REV3 59- TCAGATCCTACATAYAARTCATCIGC-392 3098–3124 266
T215Y/F ASPCR
TZ-T215 FOR 59- CACAGGGATGGAAAGGATCACC-39+ 2998–3019
TZ-T215 REV1 59- CTTCTGATGYTTYTTGTCTGGIGT-392 3185–3205
TZ-T215Y REV3 59- CTGATGYTTYTTGTCTGGIGTCTA-392 3182–3205
TZ-T215F REV4 59- CTGATGYTTYTTGTCTGGIGTCAA-392 3182–3205
TZ-T215F REV5 59- CTGATGYTTYTTGTCTGGIGTTAA-392 3182–3205 208
doi:10.1371/journal.pone.0032055.t001
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(34/50) with subtype C and two women (4%) with subtype D.
None of the 50 baseline samples exhibited preexisting drug-
selected mutations in the RT as determined by population
sequencing.
Quantification of HIV-1 RNA by outer PCR
A standard curve was calculated from eight independent runs
(r
2=0.992, standard deviation 0.004) by using defined concentra-
tions of HIV-1 NL4.3 virus ranging from 6.5610
1–10
7 copies/ml
(details in Materials and Methods S1). The lower limit of detection
for HIV-1 RNA was 650 copies/ml.
226 maternal samples (mean 4.5 samples per woman) were
available, of which 211 were successfully amplified and quantified
in the outer PCR, including 50/50 baseline samples, 48/50
delivery samples, 37/46 1–2 weeks samples (which displayed the
lowest viral load), 47/49 4–6 weeks samples and 29/31 12–16
weeks samples. Out of the seven vertically HIV-1-infected
newborns, 11/15 available samples were amplifiable in the outer
PCR.
Evaluation of ASPCR assays
Accuracy, precision, sensitivity and specificity of
ASPCR. Accuracy, precision and sensitivity (detection limit) of
all ASPCR assays are shown in Table 2. The coefficient of
variation as measurement of inter-assay precision did not exceed
47% (range 12%–47%, data not shown). The lower detection limit
for evidence of minor drug-resistant HIV-1 variants was 0.99% for
K70R, 0.04% for K103N (AAC), 0.01% for K103N (AAT), 0.35%
for Y181C, 0.63% for M184V, 0.33% for T215Y and 0.42% for
T215F (Table 2). Specificity for HIV-1 wild-type controls was
100% for all ASPCR assays.
Some maternal ASPCR results had to be excluded from analysis
due to polymorphisms in primer binding sites (details in Materials
and Methods S1); this affected two women for K103N analysis,
one woman for Y181C analysis and six women for K70R analysis.
Detection limit for drug-resistant HIV-1 in samples with
low viral load
The sensitivity of ASPCR assays for detection of drug-resistant
HIV-1 correlates with the input viral load. In order to avoid false
positiveresults, weestablisheda thresholdconsidering the respective
viral load of any given sample (see Materials and Methods S1). The
lower detection limit for drug-resistant HIV-1 variants was 0.17%
for samples with 10
4 copies/ml and 0.97% for samples with 10
3
copies/ml. If the calculated proportion of drug-resistant HIV-1 fell
below the calculated threshold, it was considered to be false positive
and presence of HIV-1 wild type was assumed; this affected the
detection of K103N and T215Y only once.
Emergence of drug-resistant HIV-1 variants in Tanzanian
women
In total, 20/50 (40%) women exhibited drug-resistant virus
during the observation period (Table 3), including 13/34 (38%)
women infected with HIV-1 subtype C, 6/14 (43%) women with
subtype A1 and 1/2 with subtype D. Genotypic mutations
associated with decreased susceptibility to AZT were detected in
11/50 (22%) women (7/50 (14%) containing K70R alone and 4/
50 (8%) with T215Y/F mutation) whereas 9/50 (18%) women
harbored NVP-resistant virus (K103N and/or Y181C). In 4/50
(8%) women a 3TC-resistance mutation (M184V) was identified,
of these 3/50 (6%) developed drug-resistant HIV-1 strains against
more than one drug (Figure 1).
In 5/20 women, drug-resistant variants were already detectable
at delivery and all of these women carried HIV-1 with AZT-
selected resistance mutations only. In 4/20 women, resistant virus
was detectable for the first time 1–2 weeks after delivery and in
11/20 women resistant variants were not present before weeks 4–
6. 50% of the women with HIV-1 resistance still exhibited drug-
resistant virus at week 12.
The first AZT-selected mutation emerging was the K70R,
which was detectable at delivery in 5/50 women in proportions of
2%–28%. The shortest interval between the start of AZT
prophylaxis and detection of the K70R mutation was 28 days
(Table 3, no 3). T215Y and T215F mutations mostly emerged
later and were measurable 1–6 weeks postpartum in 4/50 (8%)
women in low proportions of 0.5%–3.9%. One woman displayed
both AZT resistance mutations K70R and T215F in the viral
genome, which were present already at delivery and persisted
throughout the observation period at low frequencies (Table 3,
no 5).
The total median viral load reduction from baseline to delivery
was 0.6 log10; women with AZT-resistant virus at delivery
displayed significantly lower reduction (0.1 log10) compared to
women without AZT resistance at delivery (p=0.045, Mann-
Whitney U-test). Accordingly, women with AZT-resistant virus at
delivery displayed significantly higher median viral load at delivery
(29400 copies/ml) compared to women without AZT resistance at
delivery (2680 copies/ml; p=0.021, Mann-Whitney U-test).
Furthermore, women exhibiting AZT-resistant virus at delivery
had lower CD4 cell counts at baseline (331 cells/mm
3) versus
women without AZT resistance (406 cells/mm
3); this difference
marginally failed to reach statistical significance (p=0.077, Mann-
Whitney U-test).
Table 2. Accuracy, inter-assay variability and detection limit of ASPCR assays to detect drug-resistant HIV-1 variants calculated
from 7–9 independent experiments.
Input mutant allele (%) Measured mean mutant allele (% ± standard deviation)
K70R (AGA) K103N (AAC) K103N (AAT) Y181C (TGT) M184V (GTG) T215Y (TAC) T215F (TTC)
100 110 633.6 115 648.9 102 620.4 108 623.7 112 624.5 116 640.9 115 631.5
10.0 9.35 62.74 10.2 62.59 10.9 63.94 9.28 62.72 8.38 61.02 9.17 62.63 11.7 65.40
1.00 1.11 60.42 0.85 60.23 1.07 60.42 1.12 60.39 1.11 60.22 1.09 60.46 1.01 60.47
0.10 0.29 60.08 0.12 60.05 0.10 60.03 0.30 60.08 0.27 60.03 0.12 60.06 0.11 60.06
0 0.19 60.08 0.01 60.01 0.01 60.01 0.08 60.06 0.23 60.03 0.05 60.03 0.09 60.04
Detection limit (%) 0.99 0.04 0.01 0.35 0.63 0.33 0.42
doi:10.1371/journal.pone.0032055.t002
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Table 3. Drug-resistant HIV-1 variants in plasma samples of 20/50 women after complex antiretroviral prophylaxis as analyzed by
allele-specific PCR (ASPCR).
No
Sub-
type
Viral load
delivery
(cop/ml)
Antenatal
AZT-intake
(days) Results of population sequencing and ASPCR
Delivery Week 1–2 Weeks 4–6 Weeks 12–16
popseq ASPCR popseq ASPCR popseq ASPCR popseq ASPCR
1 C 1,546 58 K70R 13% K70R wt - wt
2 C 29,400 77 K70R 11% K70R wt 0.7% M184V wt -
3 A1 97,450 28 K70R 14% K70R wt wt 5.4% K70R -
4 A1 7,915 81 K70R 28% K70R wt K70R 14% K70R wt
5 C 37,800 81 wt 2.0% K70R
0.5% T215F
K65R 0.5% T215F wt 2.3% K70R wt 0.7% T215F
6 A1 4,806 43 wt wt 0.5%T215Y wt wt
7 A1 6,400 87 wt wt 10% K103N wt 0.8%Y181C -
8 C 3,790 49 wt wt 0.4% Y181C wt 1.3% K103N -
9 C 21,800 14 wt wt 0.6% M184V wt 3.4% K103N wt
10 A1 3,455 95 wt wt wt 4.9% K70R -
11 C 1,002 92 wt wt wt 2.7% K70R -
12 C 1,079 33 wt - wt 0.8% T215F wt
13 C 4,625 32 wt wt wt 3.9% T215Y wt
14 A1 646 65 wt wt wt 2.1% K103N -
15 C 2,150 67 wt wt wt 3.4% K103N -
16 C 2,875 49 wt wt K103NY181CV106A 36% K103N
20% Y181C
0.6% M184V
K103N 12% K103N
4.0% K70R
17 D 1,480 48 wt - wt wt 0.2% K103N
18 C 1,258 38 wt - wt wt 0.4% Y181C
19 C 1,055 56 wt wt wt G190A 1.5% Y181C
20 C 47,050 56 wt wt wt wt 1.0% M184V
wt=wild-type HIV-1.
-=no sample/not amplifiable.
doi:10.1371/journal.pone.0032055.t003
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differ significantly between the five women who displayed AZT
resistance mutation at delivery (77 days) and the 45 women
without AZT-resistance at delivery (50 days; p=0.20, Mann-
Whitney U-test). However, the frequency of AZT resistance at
delivery differed significantly in women with antenatal AZT intake
of at least 10 weeks (3/10=33%) as compared to women who took
antenatal AZT for less than 10 weeks (2/40=5%; p=0.048,
Fisher’s exact test).
NVP resistance mutations K103N and/or Y181C were detected
in postpartum samples of nine (18%) women, but the proportion of
resistant variants never exceeded 5% during the study period in 7/
9 (78%) of these women. In 2/9 (22%) women higher proportions
were detectable (Table 3, nos. 7, 16). One of these women (no. 16)
did take NVP-SD and AZT/3TC during labor, but did not receive
the postpartum AZT/3TC-tail to avoid NVP-resistance develop-
ment. This woman exhibited dual-resistant virus against NVP and
3TC at week 4–6 and dual-resistant virus against NVP and AZT
at month three. 3/9 women who had not taken AZT and/or 3TC
postpatum (Table 3, nos. 16, 17, 19) developed NVP-resistance
compared to 6/41 women who took the postpartal tail correctly
(p=0.33, Fisher’s exact test).
The 3TC-resistance mutation M184V was detected in four
women (8%) in low proportions of 0.6%–1.0% and was no longer
detectable in 3/4 women at week 12–16.
In 70% (14/20) of the women who developed drug-resistant
HIV-1 variants the relative proportions of resistant populations
never exceeded 5% during the whole study period. The range of
proportions of drug-resistant HIV-1 variants was 0.2–36% for
K103N mutants, 0.4–20% for Y181C mutants, 0.6–1.0% for
M184V mutants, 2.0–28% for K70R mutants, 0.5–3.9% for
T215Y mutants and 0.5–0.8% for T215F mutants, respectively. In
total, 34 drug-resistant variants were detected; out of these, 12
were present in proportions ,1%, 12 in proportions of 1–5%, and
10 in proportions of .5%.
Altogether, complex prophylaxis resulted in the development of
drug resistance in 40% of HIV-infected women. Out of these, 45%
carried HIV-1 with AZT-resistance mutations, 35% showed NVP
single drug-resistance, 5% 3TC single drug-resistance and 15%
dual or triple drug-resistance in the viral genome (Figure 1). A
longer duration of antenatal AZT intake seemed to increase the
risk for selection of AZT-resistance mutations. In most women
drug-resistant virus was present as minority species only.
Vertical transmission and emergence of drug-resistant
HIV-1 variants in infected infants
Blood specimens collected 4–6 weeks after birth were available
for 47/50 newborns; 5 were tested to be HIV-positive (no. 5, 6,
13, 21, 22; Table 4). In three additional cases, the 4–6 week
sample was lacking, and an earlier sample (taken at delivery, 3
days or 2 weeks postpartum) was analyzed respectively: two of
these samples were HIV-PCR positive, those infants were
therefore assumend to be HIV-1 infected (no. 23, 24; Table 4).
The third child was HIV-PCR negative, this infant was excluded
from calculation of the transmission-rate. The overall HIV-
transmission rate 4–6 weeks after birth was 14.3% (7/49 infants).
Vertical transmission was proven by phylogenetic analysis of
maternal and infant HIV-1 sequences (data not shown). We did
not observe a correlation between the vertical transmission risk of
HIV-1 with either maternal CD4 cell count at enrolment, viral
load at delivery or viral load reduction during pregnancy
(p=0.131; p=0.388; p=0.360, Mann-Whitney U-test) or with
the presence of AZT-resistant HIV-1 variants (p=0.546, Fisher’s
exact test). All children were at least exposed to maternal NVP-SD
during delivery, and 44/50 (88%) infants took an additional dose
of NVP postnatally. Eleven plasma samples of the seven HIV-
infected infants were amplifiable in outer PCR and were available
for subsequent ASPCR assays (Table 4). Three of 7 infants
developed drug-resistant virus (Table 4, nos. 5, 21 and 22). Two
infants (nos. 21 and 22) developed NVP-resistant HIV variants
while both mothers exhibited wild-type virus only during the
observation time. To one of these infants (no. 22) neither postnatal
NVP nor AZT was administered, but the child developed high
proportions of NVP-resistant virus at week 4–6. The third
newborn (no. 5) carried resistant virus against AZT (K70R) and
NVP (K103N) 4–6 weeks after birth; the mutation K70R was also
detectable in the maternal delivery sample.
Results of population-based sequencing and comparison
with ASPCR results
Population-based sequencing was conducted on all maternal
and infant samples with drug resistance mutations as determined
by ASPCR (n=34, Table 3 and Table 4) and additionally on 27
samples without indication of drug-resistant virus in the ASPCR
(data not shown).
In all samples harboring resistant virus in proportions .20%
according to ASPCR assays, population-based sequencing con-
firmed the presence of drug-resistant virus, and the presence of
mutations as identified by population-based sequencing was
always detected in the ASPCR assays (Table 3). All samples
without detectable drug-resistant HIV-1 or with drug-resistant
variants in proportions ,=10% in the ASPCR were identified to
contain HIV wild-type only by population sequencing (Table 3).
We also checked population sequences for additional AZT/
3TC/NVP-selected resistance mutations like M41L, D67N,
K70R, L210W, T215Y/F and K219QE for AZT, K65R for
3TC and L100I, K101P, V106A/M, V108I, Y188C/L/H and
G190A for NVP. Additional mutations in the HIV-1 genome were
detected in three women: One woman each harbored the V106A
(together with K103N, Y181C and M184V), the K65R (together
with T215F) and the G190A (together with Y181C) mutation,
respectively (Table 3, nos. 5, 16, 19).
Discussion
Since 2006, WHO PMTCT guidelines recommend complex
antiretroviral prophylaxis with AZT monotherapy during preg-
nancy, NVP-SD at labor onset, AZT/3TC during labor and for
one week after delivery [14,15]. Since AZT monotherapy and
usage of drugs with low genetic barriers like NVP and 3TC might
facilitate the formation of drug resistance, we aimed at monitoring
the emergence and persistence of key resistance mutations selected
by AZT, NVP and 3TC in 50 Tanzanian women from enrolment
(before start of prophylaxis) up to three months postpartum. To
our knowledge, this is the first study analyzing drug-resistance
including minority species in women who had taken the WHO
recommended complex prophylaxis.
AZT resistance
Emergence of AZT-resistant virus after starting AZT mono-
therapy during pregnancy has been reported to be low with less
than 3% occurrence [38,39]. Applying our highly sensitive
ASPCR assays capable of detecting minority species ,1%, we
detected HIV-1 with AZT-resistance mutations in a much higher
proportion of women (11/50=22%). However, population-based
sequencing, detecting minor variants in proportions only above
20%, revealed AZT-resistance mutations (K70R) in HIV-1 of only
4 women (8%). Furthermore, the women in our study displayed
Resistant HIV-1 after Antiretroviral Prophylaxis
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32055lower CD4 cell count levels (median: 390 cells/mm
3) compared to
the relatively immunocompetent women in other studies (median:
.500 cells/mm
3) [38,39]. Advanced disease stage and lowCD4 cell
counts have been shown to be associated with a higher frequency of
AZT-resistance [40,41]. This is in accordance with our finding, that
women carrying virus variants with AZT-selected mutations at
delivery displayed a 10fold higher median viral load compared to
women without AZT resistance mutation at delivery (p=0.021,
Mann-Whitney U-test). Furthermore, these women tended to
display lower CD4 cell counts (median: 331 cells/mm
3)i n
comparison to women without AZT resistance mutations (median:
406 cells/mm
3; p=0.077, Mann-Whitney U-test). In the most
recent WHO guidelines (2010), AZT prophylaxis is recommended
to start at a higher CD4 cell count level of 350 cells/mm
3 instead of
200 cells/mm
3 as in the previous 2006 guidelines. This might
contribute to reduced emergence of AZT resistant HIV-1.
The shortest interval between start of AZT exposure and the
emergence of AZT-selected mutation K70R was 28 days only.
AZT resistance mutations were detected more frequently in HIV-
1 of women who had taken AZT during pregnancy for longer than
10 weeks. In fact, in 30% of these women HIV carried AZT-
resistance mutations at delivery. It is well known from other studies
that the duration of AZT intake is associated with resistance
development [40,42,43].
K70R was the most frequently observed AZT mutation in
samples taken at delivery (n=5), while T215Y and T215F
mutations mostly emerged later during the observation period.
In fact, the K70R mutation is considered to be an early AZT
mutation and indicates the emergence of AZT-resistance followed
by M41L, T215Y/F and L210W [34]. This might be due to the
fact that for K70R one base substitution is sufficient (AAA/AAG
to AGA/AGG) while for T215Y and F two base mutations are
required (ACC to TAC=.T215Y or TTC=.T215F) [34]. 7/
11 women with HIV-1 carrying AZT-selected mutants displayed
the K70R mutation in proportions of 3%–28%, whereas T215Y/
F-carrying virus was harbored in lower proportions of 0.5%–3.9%
by four women. It is important to note that the K70R mutation
affecting HIV-1 of 7/50 (14%) women confers low level resistance
towards AZT, whereas T215Y and T215F mutations affecting
virus of 4/50 (8%) women result in high-level resistance [34,35].
While emergence of K70R is transient, AZT-resistant mutation
T215Y is reported to persist for several months up to more than
one year even after AZT discontinuation [44–46].
Antenatal AZT is supposed to reduce in-utero HIV-1
transmission. So far, it is not fully understood how exactly AZT
is preventing in-utero transmission. Viral load reduction by AZT
in pregnancy has been shown to be modest with 20.24 log10 and
20.3 log10 by Sperling [47] and Clarke [48] and with 20.6 log10
Table 4. Drug-resistant HIV-1 variants in plasma samples of seven children HIV-1 infected by vertical transmission as analyzed by
allele-specific PCR (ASPCR).
No
Sub-
type
Mother/
child
Maternal
CD4 count
(cells/ml)
Maternal
viral load
(cop/ml)
Ante-
natalAZT
(days)
Drug intake
during labor
Drug intake
postnatal Results of ASPCR
delivery week 1–2 week 4–6
week
12–16
5 C mother 344 37,800 81 NVP-SD AZT/3TC 2.0% K70Ru
0.5% T215Fu
0.5% T215Fu 2.3% K70Ru 0.7%
T215Fu
child NVP-SD AZT - - 15% K70R *
3.4% K103Nu
2.7%
K70Ru
6 A1 mother 572 4,806 43 NVP-SD AZT/
3TC
AZT/3TC wt 0.5%T215Yu wt wt
child NVP-SD AZT n/a - wt n/a
13 C mother 678 4,625 32 NVP-SD AZT/
3TC
AZT/3TC wt wt 3.9% T215Yu wt
child NVP-SD AZT wt - wt wt
21 A1 mother 231 14,850 33 NVP-SD AZT AZT/3TC wt wt wt -
child NVP-SD AZT - - 0.9% K103Nu
2.5% Y181Cu
-
22 C mother 211 1,720 60 NVP-SD - wt n/a wt -
child - - - 12% K103Nu
12% Y181Cu
-
23 C mother 612 2,110 20 NVP-SD AZT/
3TC
AZT/3TC wt wt wt wt
child NVP-SD AZT n/a wt - wt
24 A1 mother 200 5,385 46 NVP-SD AZT/
3TC
AZT/3TC wt wt wt -
child NVP-SD AZT n/a wt # --
wt=wild-type HIV-1.
n/a=not amplifiable.
-=no sample.
#=sample collected at day 3.
*=also detected by population-based sequencing.
u=not detected by population-based sequencing.
doi:10.1371/journal.pone.0032055.t004
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[49] it is rather conceivable that the child is at least also protected
by pre- and post-exposure prophylaxis than by the maternal viral
load reduction at delivery.
Since the AZT resistance mutation T215Y was shown to persist
for several month [44–46], resistant variants could be re-selected if
exposed to prophylactic AZT in future pregnancies or during
subsequent AZT-containing HAART if initiated within this period
after AZT exposure. This is of special importance for Sub-Saharan
African populations as many women give birth to more than one
child; AZT mutations may accumulate over time if AZT is used
during consecutive pregnancies.
Our results are conflicting with the WHO statement that ‘‘the
available evidence suggests that the time-limited use of AZT
monotherapy during pregnancy for prophylaxis (for approximately
six months, or less) should not be associated with a significant risk
of developing AZT resistance’’ [15]. Compared to 2006, WHO
guidelines from 2010 recommend to prepone the start of antenatal
AZT to week 14 instead of week 28 [14,15], corresponding to a 6-
month AZT monotherapy. According to our findings, prolonga-
tion of antenatal AZT may increase the frequency of AZT-
resistant virus.
NVP and 3TC resistance
NVP-selected resistance mutations that cause cross-resistance to
other NNRTIs are a major concern as NNRTIs are cornerstones
of first-line HAART in resource-constrained settings. According to
WHO guidelines, AZT/3TC should be taken by women for seven
days postpartum to counteract the long presence of subtherapeutic
NVP concentrations due to NVP’s long half-life. NVP resistance
was detected in 18% in our study group, which is a remarkable
reduction compared to up to 87% after NVP-SD intervention
[10]. The efficacy of postpartum short-course AZT/3TC-tails in
reducing NNRTI resistance after intrapartum NVP-SD has
indeed been shown in other studies [50,51]. In our study group,
8% of women exhibited 3TC-resistant virus in very low
proportions of ,1% only. The M184V mutation results in
complete resistance to 3TC and the presence of postpartum
M184V in proportions .20% has been correlated to subsequent
treatment failure using 3TC-containing HAART [52]. However,
the clinical and virological relevance of 3TC-resistant virus in low
proportions is not known. Moreover, M184V is known to be
rapidly lost upon withdrawal of 3TC.
Multiple drug resistance
In three women, resistant virus against more than one drug
emerged during the observation period. The main risk factor for
resistance development in general is incomplete adherence. The
most severely affected woman with respect to HIV-1 resistance
development (Table 3, no. 16) did not take AZT/3TC postpar-
tum; it seems reasonable to assume that this fostered resistance
development. It could be argued that the resistance development
in this woman cannot be attributed to the effect of complex
prophylaxis as it was not taken correctly. However, this might as
well realistically reflect the existing conditions in rural settings and
the challenges to adhere to a complex drug regimen.
Minor drug resistance
In 70% (14/20) of the women with development of drug-
resistant HIV-1, the resistant variants never exceeded proportions
of 5%. The clinical relevance of these minority species is not fully
understood and controversially discussed [17–24,53]. There is
evidence that minor drug-resistant variants can re-emerge in
subsequent regimens leading to failure of salvage therapy [21].
While Metzner et al. [53] reported of successful treatment despite
pre-existing minor K65R, K103N and M184V-variants in
German Truvada cohort, several other studies have shown that
the presence of drug-resistant minor variants increased the risk for
subsequent treatment failure for NNRTI- [18–24], protease
inhibitor- [17,54,55] and AZT-containing treatment [56]. While
a single NNRTI-resistance mutation confers high-level resistance
to some NNRTIs (an association with virologic failure in
efavirenz-containing regimen was found for K103N variants at
frequencies of .=0.5% by Halvas et al. [57]), resistance to PI and
AZT requires an accumulation of several mutations [58]. It is not
yet fully understood at which threshold minor resistant viral
populations may become clinically relevant. Furthermore, the
threshold might be different for each resistance mutation and also
depend on the subsequent treatment regimen. More evidence-
based data are necessary to determine the role of minor drug-
resistant HIV-1 in the response to antiretroviral therapy.
Vertical transmission and emergence of drug-resistant
HIV-1 variants in infected infants
The overall transmission rate in this study cohort of 50 mother-
infant pairs 4–6 weeks after delivery was 14.3% and thus
unexpectedly high. Neither a low CD4 cell count nor a high viral
load at delivery in the transmitting mothers could be identified as
transmission risk factors. Of 50 infants, all but one were breastfed,
including all HIV-infected infants. We could not define the exact
time of transmission for 4/7 infants due to lacking samples of
delivery and/or of week 1–2. However, at least 3/7 children were
born HIV uninfected (HIV-PCR was negative in the delivery
sample). We therefore assume that postpartal transmission via
breastmilk is the main reason for the high transmission rate.
Three of 7 infants developed drug-resistant HIV-1. In 2/3
newborns with NVP-resistant variants, mutations most likely
emerged in the infants as both mothers exhibited wild-type HIV-1
only during the observation period. One infant, who did not take
AZT and NVP postnatally (no. 22) exhibited NVP-resistant virus
in high proportions at week 4–6 which was selected most likely by
the maternal NVP dose. NVP rapidly crosses the placenta,
resulting in high NVP concentrations in the infant’s blood at birth
[59,60]. Postnatal NVP dosing of the infant only slightly elevated
the NVP levels in infants [61]. Therefore an infant whose mother
has taken NVP-SD during labor can develop NVP-resistant virus
even without postnatal ingestion of NVP.
Conclusions
Although complex antiretroviral prophylaxis decreased NVP-
selected resistance compared to NVP-SD alone, HIV-1 with AZT-
resistance mutations emerged in a substantial proportion of
women. This may impact negatively future AZT-containing
prophylaxis and HAART of the mother. In accordance with
Katzenstein [62], we believe that it should be considered to
substitute AZT monotherapy in pregnancy by HAART. There is
growing evidence that starting HAART regardless of CD4 cell
count level is highly beneficial for all HIV-infected individuals
[63–66]. Additionally, HAART during pregnancy seems to be safe
and advantageous for maternal and infant health [67–70]
although it is important to further monitor the long-term effects
of antiretroviral drugs on HIV-exposed but uninfected children
[71]. In the light of the accumulating knowledge on the
detrimental nature of untreated HIV-1, it seems justified to treat
this infectious disease as soon as it is diagnosed instead of delaying
medication until destructions of immune functions have taken
place. Therefore, we advocate for HAART for all HIV-positive
pregnant women; this equals ‘‘option B’’ in WHO guidelines of
Resistant HIV-1 after Antiretroviral Prophylaxis
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lifelong and not be stopped after delivery, as discontinuation
increases the risk of future treatment failure when restarting
HAART [72]. This approach would minimize the risk of HIV-1
transmission and of resistance development, would allow breast-
feeding and have an overall beneficial impact on HIV-1-infected
mothers and their children.
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